Ceramides for evaluating risk of cardiovascular disease
The present disclosure provides the use of two very long chain ceramides for determining the risk of cardiovascular disease.
1. A method to determine a risk of cardiovascular disease (CVD) in a subject, the method comprising:
providing or having been provided a biological sample from a subject having unknown CVD status;
extracting ceramide 24:0, and optionally ceramide 22:0 from the biological sample by protein precipitation in a solution comprising isopropanol and chloroform, resulting in an extracted sample;
injecting the extracted sample comprising a stable isotope internal standard into a liquid chromatography-mass spectrometer (LC-MS/MS) and measuring an amount of ceramide 24:0, and optionally ceramide 22:0 in the extracted sample;
wherein,
the extracted sample is separated by gradient LC comprising a mobile phase composition and a step gradient of the mobile phase composition over a period of about 5 min;
the mobile phase composition comprises solvent B comprising about 0.1% formic acid in isopropanol and, optionally, solvent A comprising about 0.1 formic acid in water; and
the step gradient comprises
(a) holding the mobile phase composition comprising about 65% solvent B and about 35% solvent A constant for about 0.5 min;
(b) changing the mobile phase composition comprising about 65% solvent B and about 35% solvent A to about 90% solvent B and about 10% solvent A over a step gradient time of about 1.5 min;
(c) changing the mobile phase composition comprising about 90% solvent B and about 10% solvent A to about 100% solvent B over the step gradient time of about 0.1 min;
(d) holding the mobile phase composition comprising about 100% solvent B constant for about 0.9 min;
(e) changing the mobile phase composition comprising about 100% solvent B to about 65% solvent B and about 35% solvent A over the step gradient time of about 0.1 min; and
(f) holding the mobile phase composition comprising about 65% solvent B and about 35% solvent A for about 1.9 min;
comparing the amount of ceramide 24:0 in the biological sample to a reference value of ceramide 24:0, and optionally comparing the amount of ceramide 22:0 in the biological sample to a reference value of ceramide 22:0; and
classifying the subject as at highest risk for CVD if the amount of ceramide 24:0 is less than the reference value of ceramide 24:0 of 1.97 μg/ml, and optionally ceramide 22:0 is less than the reference value of ceramide 22:0 of 0.523 μg/ml;
classifying the subject as at lower risk for CVD if the amount of ceramide 24:0 is less than the reference value of ceramide 24:0 of 2.45 μg/ml, and optionally ceramide 22:0 is less than the reference value of ceramide 22:0 of 0.659 μg/ml; or
classifying the subject as at least risk for CVD if the amount of ceramide 24:0 is greater than the reference value of ceramide 24:0 of 2.45 μg/ml, and optionally ceramide 22:0 is greater than the reference value of ceramide 22:0 of 0.659 μg/ml.
2. The method of claim 1 , wherein the subject has no risk factors for CVD.
3. The method of claim 1 , wherein the subject has one or more risk factors for CVD.
4. The method of claim 3 , wherein the one or more risk factors is selected from the group consisting of male gender, body mass index (BMI), high blood pressure, prior CVD, high cholesterol, and age.
5. The method of claim 1 , wherein the CVD is coronary heart disease (CHD) or heart failure (HF).
6. The method of claim 5 , wherein the CHD is selected from the group consisting of myocardial infarction (MI), coronary insufficiency, and angina pectoris.
7. The method of claim 1 , wherein the CVD is selected from the group consisting of fatal and non-fatal coronary heart disease (CHD), cerebrovascular disease, peripheral arterial disease, and heart failure.
8. The method of claim 1 , wherein
the biological sample is blood, plasma, or serum.
9. The method of claim 1 , wherein both ceramide 24:0 and ceramide 22:0 are measured.
10. A method to prevent cardiovascular disease (CVD) in a subject with unknown CVD status, the method comprising:
providing or having been provided a biological sample from a subject having unknown CVD status;
extracting ceramide 24:0, and optionally ceramide 22:0 from the biological sample by protein precipitation in a solution comprising isopropanol and chloroform, resulting in an extracted sample;
injecting the extracted sample comprising a stable isotope internal standard into a liquid chromatography-mass spectrometer (LC-MS/MS) and measuring an amount of ceramide 24:0, and optionally ceramide 22:0 in the extracted sample;
wherein,
the extracted sample is separated by gradient LC comprising a mobile phase composition and a step gradient of the mobile phase composition over a period of about 5 min;
the mobile phase composition comprises solvent B comprising about 0.1% formic acid in isopropanol and, optionally, solvent A comprising about 0.1% formic acid in water; and
the step gradient comprises
(a) holding the mobile phase composition comprising about 65% solvent B and about 35% solvent A constant for about 0.5 min;
(b) changing the mobile phase composition comprising about 65% solvent B and about 35% solvent A to about 90% solvent B and about 10% solvent A over a step gradient time of about 1.5 min;
(c) changing the mobile phase composition comprising about 90% solvent B and about 10% solvent A to about 100% solvent B over the step gradient time of about 0.1 min;
(d) holding the mobile phase composition comprising about 100% solvent B constant for about 0.9 min;
(e) changing the mobile phase composition comprising about 100% solvent B to about 65% solvent B and about 35% solvent A over the step gradient time of about 0.1 min; and
(f) holding the mobile phase composition comprising about 65% solvent B and about 35% solvent A for about 1.9 min;
comparing the amount of ceramide 24:0 in the biological sample to a reference value of ceramide 24:0, and optionally comparing the amount of ceramide 22:0 in the biological sample to a reference value of ceramide 22:0;
classifying the subject as at highest risk for CVD if the amount of ceramide 24:0 is less than the reference value of ceramide 24:0 of 1.97 μg/ml, and optionally ceramide 22:0 is less than the reference value of ceramide 22:0 of 0.523 μg/ml;
classifying the subject as at lower risk for CVD if the amount of ceramide 24:0 is less than the reference value of ceramide 24:0 of 2.45 μg/ml, and optionally ceramide 22:0 is less than the reference value of ceramide 22:0 of 0.659 μg/ml; or
classifying the subject as at least risk for CVD if the amount of ceramide 24:0 is greater than the reference value of ceramide 24:0 of 2.45 μg/ml, and optionally ceramide 22:0 is greater than the reference value of ceramide 22:0 of 0.659 μg/ml; and
treating the subject to prevent future CVD events when the subject is at highest risk or lower risk for CVD.
11. The method of claim 10 , wherein the subject has no history of CVD.
12. The method of claim 10 , wherein the subject has a history of CVD.
13. The method of claim 10 , wherein the CVD is selected from the group consisting of fatal coronary heart disease (CHD), non-fatal CHD, cerebrovascular disease, peripheral arterial disease, and heart failure.
14. The method of claim 13 , wherein the fatal or non-fatal CHD is selected from the group consisting of myocardial infarction (MI), coronary insufficiency, and angina pectoris.
15. The method of claim 10 , wherein treating the subject to prevent future CVD events comprises:
stress reduction;
diet changes comprising lowering sodium and trans fat consumption or increasing intake of fresh fruits and vegetables, whole unprocessed high-fiber grains, or healthy sources of fats and proteins;
lifestyle changes comprising cessation of smoking, exercising, alcohol in moderation, mediation, progressive relaxation, yoga, or biofeedback training;
intervention or surgery comprising balloon angioplasty and stents, balloon valvuloplasty, heart bypass surgery, open heart surgery, pacemaker or defibrillator implantation, heart transplantation, cardioconversion, atrial fibrillation and bypass tract ablation, or left ventricular assist device (LVAD); or
administration of aspirin, ACE inhibitors, angiotensin II receptor blockers, anti-arrhythmics, beta-blockers, high blood pressure medication, high cholesterol medication, diuretics, water pills, calcium channel blocker drugs, thrombolytic drugs, digoxin, nitrates, hydralazine, antiplatelet drugs, blood thinners, or corticosteroids.
16. A method for monitoring cardiovascular disease (CVD) in a subject, the method comprising:
measuring a first amount of ceramide 24:0, and optionally a first amount of ceramide 22:0, in a biological sample obtained from the subject;
classifying the subject as at a highest risk, a lower risk or at least risk of CVD; wherein
the subject is classified as at highest risk for CVD if the first amount of ceramide 24:0 is less than a reference value of ceramide 24:0 of 1.97 μg/ml, and optionally the first amount of ceramide 22:0 is less than a reference value of ceramide 22:0 of 0.523 μg/ml;
the subject is classified as at lower risk for CVD if the first amount of ceramide 24:0 is less than a reference value of ceramide 24:0 of 2.45 μg/ml, and optionally the first amount of ceramide 22:0 is less than a reference value of ceramide 22:0 of 0.659 μg/ml; or
the subject is classified as at least risk for CVD if the first amount of ceramide 24:0 is greater than a reference value of ceramide 24:0 of 2.45 μg/ml, and optionally the first amount of ceramide 22:0 is greater than a reference value of ceramide 22:0 of 0.659 μg/ml; and
then at a later time, treating the subject to prevent future CVD events when the subject is classified to be at the highest risk or at the lower risk for CVD and measuring a second amount of ceramide 24:0, and optionally a second amount of ceramide 22:0, in a biological sample obtained from the subject,
wherein a change in the second amount of ceramide 24:0, and optionally ceramide 22:0, from the first amount indicates a change in risk of the subject developing cardiovascular disease (CVD) over time,
wherein measuring the first amount of ceramide 24:0, and optionally the first amount of ceramide 22:0 and measuring the second amount of ceramide 24:0, and optionally the second amount of ceramide 22:0 comprises
providing or having been provided a biological sample from the subject:
extracting ceramide 24:0, and optionally ceramide 22:0 from the biological sample by protein precipitation in a solution comprising isopropanol and chloroform, resulting in an extracted sample;
injecting the extracted sample comprising a stable isotope internal standard into a liquid chromatography-mass spectrometer (LC-MS/MS) and measuring an amount of ceramide 24:0, and optionally ceramide 22:0 in the extracted sample; wherein,
the extracted sample is separated by gradient LC comprising a mobile phase composition and a step gradient of the mobile phase composition over a period of about 5 min;
the mobile phase composition comprises solvent B comprising about 0.1% formic acid in isopropanol and, optionally, solvent A comprising about 0.1% formic acid in water; and
the step gradient comprises
(a) holding the mobile phase composition comprising about 65% solvent B and about 35% solvent A constant for about 0.5 min;
(b) changing the mobile phase composition comprising about 65% solvent B and about 35% solvent A to about 90% solvent B and about 10% solvent A over a step gradient time of about 1.5 min;
(c) changing the mobile phase composition comprising about 90% solvent B and about 10% solvent A to about 100% solvent B over the step gradient time of about 0.1 min;
(d) holding the mobile phase composition comprising about 100% solvent B constant for about 0.9 min;
(e) changing the mobile phase composition comprising about 100% solvent B to about 65% solvent B and about 35% solvent A over the step gradient time of about 0.1 min; and
(f) holding the mobile phase composition comprising about 65% solvent B and about 35% solvent A for about 1.9 min.
17. The method of claim 16 , wherein an increase in the second amount of ceramide 24:0 compared to the first amount of ceramide 24:0, and optionally an increase in the second amount of ceramide 22:0 compared to the first amount of ceramide 22:0, indicates an abatement of disease progression and a decrease in the second amount of ceramide 24:0 compared to the first amount of ceramide 24:0, and optionally a decrease in the second amount of ceramide 22:0 compared to the first amount of ceramide 22:0, indicates disease progression.
18. The method of claim 17 , wherein the treatment comprises a first treatment and, optionally, a second treatment; and
when disease progression is indicated, the subject is administered the second treatment; or
the method is used to determine a response to the first treatment.
19. The method of claim 18 , wherein if the second amount of ceramide 24:0 increases compared to the first amount of ceramide 24:0, and optionally the second amount of ceramide 22:0 increases compared to the first amount of ceramide 22:0, then the subject is responding to the first treatment and if the second amount of ceramide 24:0 decreases or remains the same as the first amount of ceramide 24:0, and optionally the second amount of ceramide 22:0 decreases or remains the same as the first amount of ceramide 22:0, then the subject is not responding to the first treatment.
20. The method of claim 18 , wherein the first treatment or the second treatment comprises:
stress reduction;
diet changes comprising lowering sodium and trans fat consumption or increasing intake of fresh fruits and vegetables, whole unprocessed high-fiber grains, or healthy sources of fats and proteins;
lifestyle changes comprising cessation of smoking, exercising, alcohol in moderation, mediation, progressive relaxation, yoga, or biofeedback training;
intervention or surgery comprising balloon angioplasty and stents, balloon valvuloplasty, heart bypass surgery, open heart surgery, pacemaker or defibrillator implantation, heart transplantation, cardioconversion, atrial fibrillation and bypass tract ablation, or left ventricular assist device (LVAD); or
administration of aspirin, ACE inhibitors, angiotensin II receptor blockers, anti-arrhythmics, beta-blockers, high blood pressure medication, high cholesterol medication, diuretics, water pills, calcium channel blocker drugs, thrombolytic drugs, digoxin, nitrates, hydralazine, antiplatelet drugs, blood thinners, or corticosteroids.
21. The method of claim 16 , wherein an increase in the second amount of ceramide 24:0 compared to the first amount of ceramide 24:0, and optionally an increase in the second amount of ceramide 22:0 compared to the first amount of ceramide 22:0, indicates a decreased risk of disease progression and a decrease in the second amount of ceramide 24:0 compared to the first amount of ceramide 24:0, and optionally a decrease in the second amount of ceramide 22:0 compared to the first amount of ceramide 22:0, indicates an increased risk of disease progression.
22. The method of claim 21 , wherein the treatment comprises a first treatment and optionally, a second treatment; and
when an increased risk of disease progression is indicated, the subject is administered the second treatment; or
the method is used to determine a response to the first treatment.
23. The method of claim 22 , wherein if the second amount of ceramide 24:0 increases compared to the first amount of ceramide 24:0, and optionally the second amount of ceramide 22:0 increases compared to the first amount of ceramide 22:0, then the subject is responding to the first treatment and if the second amount of ceramide 24:0 decreases or remains the same as the first amount of ceramide 24:0, and optionally the second amount of ceramide 22:0 decreases or remains the same as the first amount of ceramide 22:0, then the subject is not responding to the first treatment.
24. The method of claim 16 , wherein
the biological sample is blood, plasma, or serum.